Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of therapeutics for cancer care. The company's primary marketed product is NERLYNX (neratinib), an irreversible tyrosine kinase inhibitor approved for the extended adjuvant treatment of early-stage HER2-positive breast cancer and, in combination with capecitabine, for advanced or metastatic HER2-positive breast cancer. NERLYNX is sold in the United States and the European Union, with exclusive license agreements in place for commercialization in Canada, Latin America, Greater China, Israel, Southeast Asia, Australia, New Zealand, South Korea, the Middle East, and parts of Africa. Puma also holds global rights to alisertib, an orally administered inhibitor of aurora kinase A, which is in development for metastatic breast cancer and small cell lung cancer. The company was founded in 2010.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage pumabiotechnology.com
Sector Healthcare IR page investor.pumabiotechnology.com
Tags
oncology, breast cancer, tyrosine kinase inhibitors, her2-positive, small molecule drugs, aurora kinase inhibitors, adjuvant therapy, metastatic cancer, NERLYNX, neratinib, alisertib, PB272, PB357
Press page —

Metrics

Valuation  
Market cap $ 418.531M
Market cap (USD) $ 418.531M
P/E 17.60
PEG 0.01
P/BV 2.85
P/S 1.81
P/OCF 9.09
P/FCF 9.08
Dividend yield —
Turnover / mcap —
Returns  
ROE 28.0%
ROI 20.4%
ROIC 21.2%
Profit margin 13.6%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 2,396.3%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 28
Quality score 17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009
Revenue 228.371M 230.468M 235.637M 228.031M 253.155M 225.11M 272.26M 250.991M 27.685M — — — — — — —
Net profit 31.111M 30.278M 21.591M 2K -29.126M -59.995M -75.6M -113.575M -291.955M -276.011M -239.284M -141.965M -54.659M -74.352M -10.233M —
Free cash flow 41.731M 38.862M 26.869M -15.827M 20.65M — — -24.544M -172.901M -145.977M -155.47M — — — -2.078M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009
Share price 5.95 3.05 4.33 4.23 3.04 10.26 8.75 20.35 98.85 30.7 78.4 189.27 103.53 18.76 — —
Price performance 12m 0.95 -0.3 0.02 0.39 -0.7 0.17 -0.57 -0.79 2.22 -0.61 -0.59 0.83 4.52 — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 9.67M 20.8M 28.9M 25.5M 32.5M 40.4M 47.8M 32M 53.7M
↳ YoY growth +114.8% +39.1% -11.6% +27.3% +24.1% +18.6% -33.1% +67.6%
↳ 5y CAGR +33.1% +18.2% +2.1% +16.0%
Borrowings, current (USD) — — — — 14.3M 0.00 0.00 34M 45.3M 22.5M
Borrowings, non-current (USD) — — — 95M 84M 97.1M 98.3M 65.7M 21.7M 0.00
Lease liabilities (USD) — — — 25.3M 22.6M 19.5M 16M 11.8M 7.03M 6.02M
Cash and deposits (USD) 194M 81.7M 108M 60M 85.3M 63.1M 76.2M 84.6M 69.2M 29.6M
Intangible assets (USD) — 48.4M 44.4M 40.5M 74.1M 66.1M 70.6M 60.9M 51.1M 41.4M
Right-of-use assets (USD) — — — 18.5M 16.4M 14M 11.4M 7.79M 4.58M 5.37M
Net debt (borrowings + leases - cash) (USD) — — — 60.2M 35.7M 53.5M 38.1M 26.9M 4.86M -1.09M
Cash flow detail
Operating cash flow (USD) -142M -172M -24.1M 22.4M 800,000 20.7M -15.8M 27M 38.9M 41.8M
Purchases of property, plant and equipment (USD) -4.29M -431,000 -439,000 -306,000 -46,000 0.00 0.00 -140,000 -56,000 -71,000
Purchases of intangible assets (USD) — -50M — 0.00 -20M 0.00 0.00 -12.5M 0.00 0.00
Change in receivables (cash effect) (USD) — -9.67M -11.1M -8.12M 2.35M -5.98M -7.82M -8.37M 16.3M -21.3M
Change in inventories (cash effect) (USD) — -2.03M -596,000 -545,000 -284,000 -3.66M 2.58M -2.55M -1.64M 3.21M
Change in payables (cash effect) (USD) 2.23M 7.66M -7.01M -1.53M -7.11M -902,000 -4.73M 449,000 -1.38M -453,000
Interest paid (cash effect) (USD) — -334,000 -8.06M -11.7M -9.7M -10.3M -10.3M -11.6M -10.8M -5.82M
Income taxes paid (cash effect) (USD) — — -17,000 -53,000 -207,000 -324,000 -384,000 -737,000 -1.22M -1.27M
Share-based compensation (USD) 117M 109M 86.9M 57.3M 36.6M 32.6M 11.8M 10.2M 8.25M 6.94M
Operating cash flow before change in receivables (USD) — -163M -13M 30.5M -1.55M 26.6M -8M 35.4M 22.6M 63.1M
Free cash flow (OCF - PPE - intangibles) (USD) -146M -223M -24.5M 22.1M -9.27M 20.7M -15.8M 14.4M 38.9M 41.7M
Income detail
Research and development expense (USD) 223M 208M 165M 133M 97.7M 71.9M 52.2M 50.4M 54.9M 62.1M
↳ 5y CAGR +206.3% +33.2% +29.6% +1.6% -14.1% -20.3% -24.1% -21.1% -16.2% -8.7%
Total comprehensive income (USD) -276M -292M -114M -75.5M -60.1M -29.1M 4,000 21.6M 30.3M 31.1M
Comprehensive income to owners (USD) -276M -292M -114M -75.5M -60.1M -29.1M 4,000 21.6M 30.3M 31.1M
Provision for credit losses (USD) — — — 0.00 1M 0.00 0.00 881,000 -519,000 -362,000
Credit cost ratio (credit losses / average receivables) (%) — — — 0.0% 3.7% 0.0% 0.0% 2.0% 1.3% 0.8%
Reported Mar 1, 2017 Mar 9, 2018 Mar 1, 2021 Mar 3, 2022 Mar 3, 2022 Mar 3, 2022 Aug 3, 2023 Feb 29, 2024 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

PDF Version

- Third quarter U.S. NERLYNX sales driven by increased year-over-year demand**- Raising 2026 net income guidance**

LOS ANGELES--(BUSINESS WIRE)--Nov. 5, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2026. Unless otherwise stated, all comparisons are for the third quarter of 2026 compared to the third quarter of 2025.

Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the third quarter of 2026 was $54.1 million, compared to product revenue, net of $51.9 million in the third quarter of 2025. Product revenue, net in the first nine months of 2026 was $149.6 million, compared to $144.2 million in the first nine months of 2025.

Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $6.0 million, or $0.12 per basic share and $0.11 per diluted share, for the third quarter of 2026, compared to net income of $8.8 million, or $0.18 per basic share and $0.17 per diluted share, for the third quarter of 2025. Net income for the first nine months of 2026 was $10.4 million, or $0.20 per basic and diluted share, compared to net income of $17.7 million, or $0.35 per basic and diluted share, for the first nine months of 2025.

Non-GAAP adjusted net income was $8.0 million, or $0.15 per basic and diluted share, for the third quarter of 2026, compared to non-GAAP adjusted net income of $10.5 million, or $0.21 per basic and diluted share, for the third quarter of 2025. Non-GAAP adjusted net income for the first nine months of 2026 was $16.3 million, or $0.32 per basic share and $0.31 per diluted share, compared to non-GAAP adjusted net income of $23.0 million, or $0.46 per basic and diluted share, for the first nine months of 2025. Non-GAAP adjusted net income excludes stock-based compensation expense. For a reconciliation of GAAP net income to non-GAAP adjusted net income and GAAP net income per share to non-GAAP adjusted net income per share, please see the financial tables at the end of this news release.

Net cash provided by operating activities for the third quarter of 2026 was $14.6 million, compared to $9.7 million in the third quarter of 2025. Net cash provided by operating activities for the first nine months of 2026 was $31.6 million, compared to net cash provided by operating activities of $27.4 million in the first nine months of 2025. At September 30, 2026, Puma had cash, cash equivalents and marketable securities of $108.5 million, compared to cash, cash equivalents and marketable securities of $97.5 million at December 31, 2025.

“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and 340B sales, as well as a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter,” said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. “We continue to anticipate increased year-over-year demand for NERLYNX, while we continue to advance alisertib across our ALISCA® clinical development programs. During the quarter, we initiated ALISCA®-Lung2, a Phase II trial evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer, further expanding our clinical development program in this area, while we are continuing to enroll the ALISCA®-Breast1 and ALISCA®-Lung1 trials.”

Mr. Auerbach added, “We anticipate the following key milestones over the next 12 months: (i) presentation of updated data from ALISCA®-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (San Antonio Breast Cancer Symposium, December 2026); (ii) initiation of discussions with global regulatory agencies regarding the Phase III trial design for alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (H1 2027); (iii) continued enrollment in ALISCA®-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer to obtain more data in biomarker focused populations (H2 2026); (iv) continued enrollment of ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer and ALISCA®-Lung2, a Phase II trial evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer (Q4 2026); and (v) presentation of updated data from ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (2027).”

Revenue

Total revenue consists of product revenue, net from sales of NERLYNX, Puma’s first commercial product, and royalty revenue. For the third quarter ended September 30, 2026, total revenue was $55.1 million, of which $54.1 million was net product revenue and $1.0 million was royalty revenue. This compares to total revenue for the third quarter of 2025 of $54.5 million, of which $51.9 million was net product revenue and $2.6 million was royalty revenue. For the first nine months of 2026, total revenue was $156.4 million, of which $149.6 million was net product revenue and $6.8 million was royalty revenue. This compares to total revenue for the first nine months of 2025 of $152.9 million, of which $144.2 million was net product revenue and $8.7 million was royalty revenue. The third quarter and first nine months of 2026 included a $2.1 million reduction to royalty revenue as a change in accounting estimate, reflecting the receipt of new third-party market data confirming that the market share of generic versions of NERLYNX in China reached a specified threshold during the period.

Operating Costs and Expenses

Total operating costs and expenses were $49.8 million for the third quarter of 2026, compared to $44.9 million for the third quarter of 2025. Operating costs and expenses in the first nine months of 2026 were $147.4 million, compared to $132.7 million in the first nine months of 2025. The year-to-date increases were primarily attributable to increases in R&D expenses and cost of sales.

Cost of Sales

Cost of sales was $15.2 million for the third quarter of 2026, compared to $12.2 million for the third quarter of 2025. Cost of sales was $38.1 million for the first nine months of 2026, compared to $35.0 million for the first nine months of 2025. The increases in cost of sales for the third quarter and first nine months of 2026 were due primarily to higher product sales to an international partner.

Selling, General and Administrative Expenses

Selling, general and administrative (SG&A) expenses were $16.3 million for the third quarter of 2026, compared to $16.8 million for the third quarter of 2025. SG&A expenses for the first nine months of 2026 were $52.3 million, compared to $52.5 million for the first nine months of 2025, and were virtually unchanged year over year.

Research and Development Expenses

Research and development (R&D) expenses were $18.3 million for the third quarter of 2026, compared to $15.9 million for the third quarter of 2025. R&D expenses for the first nine months of 2026 were $57.0 million, compared to $45.2 million for the first nine months of 2025. The $11.8 million year-over-year increase for the first nine months resulted primarily from an $8.9 million increase in clinical trial expense, reflecting increased alisertib study activity, and an increase of approximately $2.9 million in internal R&D expense, primarily due to increased employee compensation including the hiring of a new executive.

Total Other Income (Expenses)

Total other income was $0.9 million for the third quarter of 2026, compared to total other expenses of $0.4 million for the third quarter of 2025. Total other income was $2.0 million for the first nine months of 2026, compared to total other expenses of $1.5 million for the first nine months of 2025. The $3.5 million year-over-year increase in other income for the first nine months of 2026 resulted primarily from a decrease in interest expense, reflecting a lower debt balance, as Puma paid down its debt principal in May 2026, partially offset by the termination of subleases as of March 31, 2026 and unfavorable exchange rates on Euro-denominated transactions.

Fourth Quarter and Full Year 2026 Financial Outlook

| | Fourth Quarter 2026 | New Full Year 2026 | Prior Full Year 2026 |

| Net Product Revenue | $56–$58 million | $206–$208 million | $205–$209 million |

| Royalty Revenue | $11–$12 million | $18–$19 million | $19–$22 million |

| Total Revenue | $67–$70 million | $224–$227 million | $224–$231 million |

| Net Income* | $10–$12 million | $20–$22 million | $17–$20 million |

| Gross to Net Adjustment | 28%–29% | 27.5%–28% | 26.5%–27.5% |

*The outlook above does not include any potential adjustments for tax valuation allowance.

Conference Call

Puma Biotechnology will host a conference call to report its third quarter 2026 financial results and provide an update on the Company’s business and outlook at 1:30 p.m. PT/4:30 p.m. ET on Thursday, November 5, 2026. The call may be accessed by dialing (877) 709-8150 (domestic) or (201) 689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of the call and will be archived on Puma’s website for 90 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer. In November 2024, Puma initiated ALISCA®-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. In September 2026, Puma initiated ALISCA®-Lung2, a Phase II clinical trial of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. ALISCA® is a registered trademark of Puma Biotechnology, Inc.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at https://www.NERLYNX.com or by calling 1-855-816-5421.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

INDICATIONS

NERLYNX® (neratinib) tablets, for oral use, is a kinase inhibitor indicated:

  • As a single agent, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.

  • In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer, who have received two or more prior anti-HER2 based regimens in the metastatic setting.

Important Safety Information Regarding NERLYNX® (neratinib) U.S. Indication

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

  • Diarrhea: Manage diarrhea through either NERLYNX dose escalation or loperamide prophylaxis. If diarrhea occurs despite recommended prophylaxis, treat with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold NERLYNX in patients experiencing severe and/or persistent diarrhea. Permanently discontinue NERLYNX in patients experiencing Grade 4 diarrhea or Grade ≥ 2 diarrhea that occurs after maximal dose reduction.

  • Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.

  • Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS: The most common adverse reactions (reported in ≥ 5% of patients) were as follows:

  • NERLYNX as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.

  • NERLYNX in combination with capecitabine: diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-332-1088 orwww.fda.gov/medwatch.

DRUG INTERACTIONS:

  • Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. Separate NERLYNX by at least 2 hours before or 10 hours after H2-receptor antagonists. Or separate NERLYNX by at least 3 hours after antacids.

  • Strong CYP3A4 inhibitors: Avoid concomitant use.

  • P-gp and moderate CYP3A4 dual inhibitors: Avoid concomitant use.

  • Strong or moderate CYP3A4 inducers: Avoid concomitant use.

  • Certain P-gp substrates: Monitor for adverse reactions of P-gp substrates for which minimal concentration change may lead to serious adverse reactions when used concomitantly with NERLYNX.

USE IN SPECIFIC POPULATIONS:

  • Lactation: Advise women not to breastfeed.

Please see Full Prescribing Information for additional safety information.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding Puma’s anticipated milestones and estimates of future financial results for the fourth quarter and full year 2026. All forward-looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on Puma’s business or the global economy and financial markets, any changes in Puma’s product candidates’ regulatory approvals, results from Puma’s clinical trials, any litigation involving Puma, any changes to Puma’s in-licensed intellectual property and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Puma’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

| PUMA BIOTECHNOLOGY, INC. AND SUBSIDIARY |

| CONSOLIDATED STATEMENTS OF OPERATIONS |

| (in millions except share and per share data) |

| | | | | | | |

| | | Three Months Ended | | | Nine Months Ended | |

| | | September 30, | | | September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| | | (Unaudited) | | | (Unaudited) | | | (Unaudited) | | | (Unaudited) | |

| Revenues: | | | | ​ | | | | ​ | | | | ​ | | | | ​ |

| Product revenue, net | | $ | 54.1 | | | $ | 51.9 | | | $ | 149.6 | | | $ | 144.2 | |

| Royalty revenue | | | 1.0 | | | | 2.6 | | | | 6.8 | | | | 8.7 | |

| Total revenue | | | 55.1 | | | | 54.5 | | | | 156.4 | | | | 152.9 | |

| Operating costs and expenses: | | | | ​ | | | | ​ | | | | ​ | | | | ​ |

| Cost of sales | | | 15.2 | | | | 12.2 | | | | 38.1 | | | | 35.0 | |

| Selling, general and administrative | | | 16.3 | | | | 16.8 | | | | 52.3 | | | | 52.5 | |

| Research and development | | | 18.3 | | | | 15.9 | | | | 57.0 | | | | 45.2 | |

| Total operating costs and expenses | | | 49.8 | | | | 44.9 | | | | 147.4 | | | | 132.7 | |

| Income from operations | | | 5.3 | | | | 9.6 | | | | 9.0 | | | | 20.2 | |

| Other income (expenses): | | | | ​ | | | | ​ | | | | ​ | | | | ​ |

| Interest income | | | 0.9 | | | | 1.0 | | | | 2.7 | | | | 3.1 | |

| Interest expense | | | — | | | | (1.5 | ) | | | (0.9 | ) | | | (5.5 | ) |

| Other income | | | — | | | | 0.1 | | | | 0.2 | | | | 0.9 | |

| Total other income (expenses), net | | | 0.9 | | | | (0.4 | ) | | | 2.0 | | | | (1.5 | ) |

| Net income before income taxes | | | 6.2 | | | | 9.2 | | | | 11.0 | | | | 18.7 | |

| Income tax expense | | | (0.2 | ) | | | (0.4 | ) | | | (0.6 | ) | | | (1.0 | ) |

| Net income | | $ | 6.0 | | | $ | 8.8 | | | $ | 10.4 | | | $ | 17.7 | |

| Net income per share of common stock—basic | | $ | 0.12 | | | $ | 0.18 | | | $ | 0.20 | | | $ | 0.35 | |

| Net income per share of common stock—diluted | | $ | 0.11 | | | $ | 0.17 | | | $ | 0.20 | | | $ | 0.35 | |

| Weighted-average shares of common stock outstanding—basic | | | 51,602,295 | | | | 50,339,456 | | | | 51,131,897 | | | | 49,881,181 | |

| Weighted-average shares of common stock outstanding—diluted | | | 53,116,836 | | | | 50,929,893 | | | | 52,605,014 | | | | 50,334,553 | |

| PUMA BIOTECHNOLOGY, INC. AND SUBSIDIARY |

| LIQUIDITY AND CAPITAL RESOURCES |

| (in millions) |

| | | | | | | |

| | | September 30, | | | December 31, | |

| | | 2026 | | | 2025 | |

| Cash and cash equivalents | | $ | 41.5 | | | $ | 29.6 | |

| Marketable securities | | | 67.0 | | | | 67.9 | |

| Working capital | | | 105.7 | | | | 81.4 | |

| Current portion of long-term debt | | | — | | | | 22.5 | |

| Stockholders’ equity | | | 146.6 | | | | 130.3 | |

| | | Nine Months Ended | | | Nine Months Ended | |

| | | September 30, 2026 | | | September 30, 2025 | |

| Cash provided by (used in): | | | | ​ | | | | ​ |

| Operating activities | | $ | 31.6 | | | $ | 27.4 | |

| Investing activities | | | 0.7 | | | | (9.2 | ) |

| Financing activities | | | (22.5 | ) | | | (33.9 | ) |

| Net increase (decrease) in cash, cash equivalents, and restricted cash | | $ | 9.8 | | | $ | (15.7 | ) |

Use of Non-GAAP Measures

In addition to operating results as calculated in accordance with GAAP, Puma uses certain non-GAAP financial measures when planning, monitoring and evaluating operational performance. The following table presents Puma’s net income and net income per share calculated in accordance with GAAP and as adjusted to remove the impact of stock-based compensation expense. For the three months and nine months ended September 30, 2026, stock-based compensation represented approximately 5.8% and 5.4% of operating expenses, respectively, and 5.1% and 5.5% for the same periods in 2025, in each case excluding cost of sales. Puma’s management believes that these non-GAAP financial measures are useful to enhance understanding of Puma’s financial performance, are more indicative of its operational performance, and facilitate a better comparison among fiscal periods. These non-GAAP financial measures are not, and should not be viewed as, substitutes for GAAP reporting measures.

| PUMA BIOTECHNOLOGY, INC. AND SUBSIDIARY |

| Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income and |

| GAAP Net Income Per Share to Non-GAAP Adjusted Net Income Per Share |

| (in millions except share and per share data) |

| (Unaudited) |

| | | | | |

| | | Three Months Ended September 30, | | |

| | | 2026 | | | | 2025 | | |

| GAAP net income | | $ | 6.0 | | | | $ | 8.8 | | |

| Adjustments: | | | | | | | | | | |

| Stock-based compensation - | | | | | | | | | | |

| Selling, general and administrative (1) | | | 1.3 | | | | | 1.1 | | |

| Research and development (2) | | | 0.7 | | | | | 0.6 | | |

| Non-GAAP adjusted net income | | $ | 8.0 | | | | $ | 10.5 | | |

| | | | | | | | | | | |

| GAAP net income per share—basic | | $ | 0.12 | | | | $ | 0.18 | | |

| Adjustment to net income (as detailed above) | | | 0.03 | | | | | 0.03 | | |

| Non-GAAP adjusted basic net income per share | | $ | 0.15 | | (3) | | $ | 0.21 | | (4) |

| | | | | | | | | | | |

| GAAP net income per share—diluted | | $ | 0.11 | | | | $ | 0.17 | | |

| Adjustment to net income (as detailed above) | | | 0.04 | | | | | 0.04 | | |

| Non-GAAP adjusted diluted net income per share | | $ | 0.15 | | (5) | | $ | 0.21 | | (6) |

| | | Nine Months Ended September 30, | | |

| | | 2026 | | | | 2025 | | |

| GAAP net income | | $ | 10.4 | | | | $ | 17.7 | | |

| Adjustments: | | | | | | | | | | |

| Stock-based compensation - | | | | | | | | | | |

| Selling, general and administrative (1) | | | 3.6 | | | | | 3.3 | | |

| Research and development (2) | | | 2.3 | | | | | 2.0 | | |

| Non-GAAP adjusted net income | | $ | 16.3 | | | | $ | 23.0 | | |

| | | | | | | | | | | |

| GAAP net income per share—basic | | $ | 0.20 | | | | $ | 0.35 | | |

| Adjustment to net income (as detailed above) | | | 0.12 | | | | | 0.11 | | |

| Non-GAAP adjusted basic net income per share | | $ | 0.32 | | (3) | | $ | 0.46 | | (4) |

| | | | | | | | | | | |

| GAAP net income per share—diluted | | $ | 0.20 | | | | $ | 0.35 | | |

| Adjustment to net income (as detailed above) | | | 0.11 | | | | | 0.11 | | |

| Non-GAAP adjusted diluted net income per share | | $ | 0.31 | | (5) | | $ | 0.46 | | (6) |

| (1) To reflect a non-cash charge to operating expense for selling, general and administrative stock-based compensation. |

| (2) To reflect a non-cash charge to operating expense for research and development stock-based compensation. |

| (3) Non-GAAP adjusted basic net income per share was calculated based on 51,602,295 and 51,131,897 weighted-average shares of common stock outstanding for the three and nine months ended September 30, 2026, respectively. |

| (4) Non-GAAP adjusted basic net income per share was calculated based on 50,339,456 and 49,881,181 weighted-average shares of common stock outstanding for the three and nine months ended September 30, 2025, respectively. |

| (5) Non-GAAP adjusted diluted net income per share was calculated based on 53,116,836 and 52,605,014 weighted-average shares of common stock outstanding for the three and nine months ended September 30, 2026, respectively. |

| (6) Non-GAAP adjusted diluted net income per share was calculated based on 50,929,893 and 50,334,553 weighted-average shares of common stock outstanding for the three and nine months ended September 30, 2025, respectively. |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105266638/en/

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 [email protected] [email protected]

David Schull, Russo Partners, +1 212 845 4200 [email protected]

Source: Puma Biotechnology, Inc.

Search Investors

November 4, 2026

PDF Version

LOS ANGELES--(BUSINESS WIRE)--Nov. 4, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 2, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 18,500 shares of Puma common stock to three new non-executive employees.

The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017, and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the awards vesting on the first anniversary of the awards’ vesting commencement date, November 1, 2026, and one-sixth of the shares underlying the awards vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA®-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. In September 2026, Puma initiated ALISCA®-Lung2, a Phase II clinical trial of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. ALISCA® is a registered trademark of Puma Biotechnology, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104308437/en/

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 [email protected] [email protected]

Source: Puma Biotechnology, Inc.

Search Investors

October 22, 2026

PDF Version

LOS ANGELES--(BUSINESS WIRE)--Oct. 22, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, November 5, 2026, following the release of its third quarter 2026 financial results.

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of the call and will be archived on Puma’s website for 90 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX® was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX® was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA®-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. In September 2026, Puma initiated ALISCA®-Lung2, a Phase II clinical trial of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. ALISCA® is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261022355038/en/

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 [email protected] [email protected]

David Schull, Russo Partners, +1 212 845 4200 [email protected]

Source: Puma Biotechnology, Inc.

Search Investors

Prompts

Puma Biotechnology Inc (ticker PBYI), listed in United States.

Company History

Date Change Detail
Oct 6, 2011 Renamed INNOVATIVE ACQUISITIONS CORP → PUMA BIOTECHNOLOGY, INC.

ETFs Holding Puma Biotechnology Inc

ETF Weight in ETF Shares Market value As of
OASC 0.37% 38,387 $ 349.706K Aug 31, 2026
LITL 0.37% 2,948 $ 21.049K Nov 17, 2026
SQLV 0.28% 9,881 $ 80.135K Jun 30, 2026
IVSS 0.09% 2,976 $ 24.135K Jun 30, 2026
VFQY 0.08% 42,945 $ 391.229K Aug 31, 2026
BSVO 0.07% 248,990 $ 1.78M Nov 18, 2026
AVUV 0.06% 2,570,584 $ 18.868M Nov 16, 2026
FEAC 0.05% 1,725 $ 13.99K Jun 30, 2026
FESM 0.02% 177,567 $ 1.44M Jun 30, 2026
AVSC 0.02% 96,106 $ 705.418K Nov 16, 2026
VFMF 0.02% 20,939 $ 190.754K Aug 31, 2026
DFAT 0.01% 384,736 $ 3.109M Nov 12, 2026
DFAS 0.01% 380,741 $ 3.076M Nov 12, 2026
VFMO 0.01% 15,820 $ 144.12K Aug 31, 2026
EBI 0.01% 5,372 $ 48.939K Aug 31, 2026
DXUV 0.00% 28,112 $ 227.145K Nov 12, 2026
MSSM 0.00% 1,951 $ 17.774K Aug 31, 2026
DFSV 0.00% 53,015 $ 428.361K Nov 12, 2026
DFAU 0.00% 12,537 $ 101.299K Nov 12, 2026
DFUS 0.00% 15,090 $ 121.927K Nov 12, 2026
DCOR 0.00% 20,680 $ 167.094K Nov 12, 2026
DFAC 0.00% 17,782 $ 143.679K Nov 12, 2026
AVUS 0.00% 34,919 $ 256.305K Nov 16, 2026